What diseases does ibrutinib/ibrutinib capsules mainly treat?

Ibrutinib/Ibrutinib belongs to the kinase inhibitor class of drugs. It prevents cancer cells from multiplying by blocking the action of abnormal proteins. This helps stop the spread of cancer cells. Ibrutinib is mainly used for the treatment of the following indications:

1. Treatment of patients with mantle cell lymphoma (MCL; a fast-growing cancer that starts in immune system cells) who have been treated with at least one other chemotherapy drug,

2. Treat patients with chronic lymphocytic leukemia (CLL; a cancer that starts in white blood cells) and small lymphocytic lymphoma (SLL; a cancer that starts mainly in lymph nodes),

3. Treating patients with Waldenström's macroglobulinemia (WM; a slow-growing cancer that starts in certain white blood cells in the bone marrow),

4. Treatment of patients with marginal zone lymphoma (MZL; a slow-growing cancer that begins in a type of white blood cell that normally fights infection) who have been treated with some type of chemotherapy drug,

5. Treat patients with chronic graft-versus-host disease (cGVHD; a complication of hematopoietic stem cell transplantation [HSCT; a procedure in which diseased bone marrow is replaced with healthy bone marrow] that may begin some time after transplantation and last long after transplantation) after treatment with one or more drugs has failed.

Ibrutinib is available in capsule and tablet oral forms. Usually taken once daily. Take ibrutinib at about the same time each day, and do not take more or less or more often than prescribed by your doctor. Swallow capsules whole with a glass of water; do not open, break or chew them. Swallow the tablets whole with a glass of water; do not cut, crush, or chew them. Continue taking ibrutinib even if you feel well, and do not stop taking ibrutinib without talking to your doctor.